Containing cefoxitin costs through a program to curtail use in surgical prophylaxis

GEOFFREY TAYLOR, MD, EDITH BLONDEL-HILL, MD, PAMELA KIBSEY, MD, ERWIN FRIESEN, PHARM D, RONALD TISDELL, BSC, WENDY VAUDRY, MD


OBJECTIVE: To reduce drug costs attributable to anti-anaerobic cephalosporins – specifically to reduce cefoxitin use in surgical prophylaxis. DESIGN: Before and after intervention cefoxitin use comparison. SETTING: Tertiary care hospital. PARTICIPANTS: Hospitalized patients. INTERVENTIONS: Chart review of patients identified through pharmacy records as cefoxitin recipients was carried out to determine which physicians were the principal users of cefoxitin and the purpose for such use. These data were used to direct cost containment strategies. MAIN OUTCOME MEASURES: Hospital quarterly pharmacy acquisition costs and grams of cefoxitin used. RESULTS: The departments of surgery (49%) and obstetrics/gynecology (37%) were the principal users of cefoxitin, and surgical prophylaxis was found to be the principal indication for use (63%). These departments were invited by the Antibiotic Utilization Subcommittee of the hospital's Pharmacy and Therapeutics Committee to draft surgical prophylaxis guidelines in keeping with published recommendations. Such guidelines were written and distributed to medical staff and substituted cefazolin for most forms of prophylaxis, gentamicin/metronidazole for colorectal prophylaxis and cefoxitin only for appendectomies. Over the following 21 months, hospital-wide cefoxitin use fell from 6093 g, $70,076 per quarter, to 1316 g, $11,515 per quarter (partially offset by a 2595 g, $9,131 per quarter increase in cefazolin use). CONCLUSION: As a first step in reducing hospital costs of anti-anaerobic cephalosporins, rationalization of cefoxitin use may be preferable to formulary interchange with alternatives such as ceftriaxone or cefotetan.

Key Words: Antibiotic cost containment. Cefoxitin. Surgical prophylaxis

Comment limiter les coûts de la cefoxitine au moyen d’un programme de réduction de son utilisation en prophylaxie chirurgicale

OBJECTIF : Diminuer les coûts de l’utilisation des céphalosporines anti-anaérobies et tout particulièrement en réduisant l’utilisation de la cefoxitine en prophylaxie chirurgicale. MÉTHODOLOGIE : Comparaison de l’utilisation de la cefoxitine avant et après intervention du programme. CADRE : Hôpital de soins tertiaires. PARTICIPANTS : Patients hospitalisés. INTERVENTIONS : Une revue détaillée des patients identifiés grâce aux registres de la pharmacie comme ayant reçu de la cefoxitine, a été effectuée afin de déterminer les médecins qui étaient les principaux utilisateurs de cefoxitine ainsi que la but de cette utilisation. Les données obtenues ont été utilisées pour préparer des stratégies de réduction des coûts. PRINCIPAUX INDICATEURS DES RÉSULTATS : Coûts d’acquisition trimestriels de la pharmacie de l’hôpital et nombre de grammes de cefoxitine utilisés. RÉSULTATS : Les services de chirurgie (49 %) et d’obstétrique/gynécologie (37 %) ont été les principaux utilisateurs de cefoxitine, et la prophylaxie chirurgicale a été notée comme le principal objet de son indication : 66 %. Ces services ont été invités par le sous-comité d’utilisation des antibiotiques du comité de pharmacologie et de thérapeutique de l’hôpital à établir des directives de prophylaxie chirurgicale en accord avec les recommandations publiées. Ces directives ont été rédigées et distribuées au personnel médical : elles consistent à...
remplacer la céfoxitine par la céfazoline pour la plupart des formes de prophylaxie; par la gentamicine/métronidazole pour la prophylaxie colorectale, en réservant la céfoxitine uniquement aux appendicectomies. Pendant les 21 mois suivants, l'utilisation de la céfoxitine dans tout l'hôpital est passée de 6 093 g, soit 70 076 $ par trimestre, à 1 316 g, c'est-à-dire 11 515 $ par trimestre (différence partiellement compensée par une augmentation de 2 595 g, soit 9 131 $ par trimestre de frais d'utilisation de la céfoxitine). Conclusion : En première étape du programme de réduction des coûts hospitaliers des céphalosporines anti-anaérobies, la rationalisation de l'utilisation de la céfoxitine est préférable aux substitutions par d'autres produits du formulaire comme le cefotizoxime ou le cefotéitan.

MODERN ANTIMICROBIAL DRUG THERAPY OF HOSPITALIZED patients, while highly efficacious, can also be expensive. In North American hospitals, antimicrobials consume 20 to 40% of all drug acquisition costs (1,2). Cephalosporin antimicrobials are particularly expensive, accounting for 36 to 59% of antimicrobial purchase costs (3,4). Cefotixin, a second generation cephalosporin with a broad spectrum of activity against aerobic Gram-negative and Gram-positive bacteria as well as anti-anaerobic bacterial activity (5), has been a very popular drug for in-hospital use since its introduction in the 1970s. In 1984 cefotixin led all other drugs in the United States in terms of hospital sales (4). There is, however, substantial published evidence of widespread use of cefotixin when narrower spectrum (and less expensive) agents would suffice (4,6).

Recently, two new cephalosporin drugs with anti-anaerobic activity have been marketed in Canada as less expensive alternatives to cefotixin: cefotetan and cefetizoxime (7,8). In an effort to reduce costs of antimicrobial therapy, it has been suggested that hospitals might delete cefotixin from their formularies and substitute either cefotetan or cefetizoxime (9-11); however, merely to substitute one of these newer agents for cefotixin could be regarded as substituting one inappropriately used agent for another. Rather than substitute cefotetan or cefetizoxime for cefotixin, we chose to determine to what extent cefotixin misuse was occurring in our hospital and tried to improve its use.

METHODS

The University of Alberta Hospital is an 1100 bed tertiary care hospital serving northern Alberta. The annual drug acquisition budget has been in the order of $5 million with antimicrobials accounting for about 25% of this amount. Cefotixin has traditionally been among the top five drugs in terms of acquisition costs, with steadily increasing expenditures. In the fiscal year 1984-85, $159,355 was spent acquiring 19,920 g of cefotixin; by 1989-90 this had increased to $238,882 to acquire 19,770 g (reflecting a price increase from $8.00 to $11.50/g).

In the spring of 1990, at a time of serious budgetary crisis for the authors' hospital, the Antibiotic Utilization Subcommittee of the hospital's Pharmacy and Therapeutics Committee decided to target cefotixin as part of its cost containment strategy. A previously completed chart review study of 152 consecutive courses of cefotixin use in the same institution had shown that the majority of use was in the departments of surgery (49% of cases) and obstetrics/gynecology (37%) (unpublished data). This study also showed that 63% of all patients receiving cefotixin did so for the purpose of surgical prophylaxis and only 37% of treatment courses were given to manage established infection. Efforts were, therefore, principally directed at these two groups and, in particular, at their antibiotic prophylaxis regimens.

The subcommittee invited the departments of obstetrics/gynecology and surgery to participate in a review of cefotixin use. Neither department had developed guidelines for antibacterial surgical prophylaxis, leaving the decision as to which patients would be given prophylaxis, which agents would be used and duration of prophylaxis to individual surgeons. It was pointed out that while it is an effective prophylactic agent, cefotixin had not been shown to be superior to other agents for any surgical procedure and was not recommended as a first-line prophylactic agent for any indication except appendectomy (12-14). Following a review of the literature, the departments agreed to draw up routine surgical prophylaxis guidelines. In keeping with published guidelines, cefazolin was specified as the agent of choice for head and neck, gastroduodenal, high risk biliary tract, hysterectomy and high risk caesarean section surgical procedures. Metronidazole plus gentamicin were chosen for colonic surgery (15) and cefotixin for appendectomy (14). Guidelines were distributed to attending physicians and residents in the departments of surgery and obstetrics/gynecology, and additional cefotixin information was included in a Pharmacy and Therapeutics Committee newsletter to all medical staff. To forestall any pharmaceutical industry response to declining cefotixin use it was made clear that failure of this approach would very likely lead to complete elimination of cefotixin from the formulary.

To observe the outcome of the interventions, hospital-wide pharmacy cefotxin acquisition data (total grams and costs) were analyzed over 21 months from the initiation of the process (April 1990 to December 1991).

RESULTS

For the fiscal year 1989-90, ie, just before implementation of the initiatives, the hospital spent $238,882 (19,770 g) or $59,720 per quarter (4942 g) on cefotixin. In the first quarter of 1990-91, during the implementation of initiatives, this rose to $70,076 (6093 g). Subsequently, there has been a fall in costs related to cefotixin acquisition (Figure 1) and number of grams...
used (Figure 2). In the third quarter of 1991 (October to December), the price of cefoxitin was reduced from $11.50 to $8.75/g adding to the cost savings. Altogether in fiscal year 1990-91 cefoxitin expenditures were $169,683, a drop of $69,199 compared with the previous fiscal year. If the level of use for the first three quarters (April to December) of 1991-92 can be maintained, the annual costs would be reduced to $56,743, a saving of $182,139 over 1989-90.

During this period, cefazolin use increased by 31% - from 8339 g in the first quarter of 1990 (April to June) to 10,934 g (October to December 1991) - but this resulted in only a $6,905 increase in per quarter costs, reflecting its much lower acquisition price ($2.45/g). These changes occurred in the context of no change to the hospital's in-patient admissions rate (mean during the study period, 2485 per month, range 2019 to 2794) or numbers of surgical procedures performed (mean 1134 per month range 892 to 1318).

**DISCUSSION**

This study has shown that considerable reductions in expenditures on anti-anaerobic cephalosporins can be achieved through a process of curtailing cefoxitin use. We feel that the concept of cefoxitin rationalization through curtailment is preferable, initially, to formulary interchange with cefotetan or ceftizoxime. Exchanging one drug for another depends on the new agent having at least an equivalent safety and therapeutic profile to the older agent. In our opinion, cefotetan and ceftizoxime, while promising, have not been shown to be equal in clinical efficacy or safety to cefoxitin for treatment or prophylaxis (7,16-18). Furthermore, the concept of reducing costs through the interchange process assumes the older agent is already being used in the most cost effective manner (clearly not the case with cefoxitin in many hospitals). Finally, drug interchange depends on the newer agent being used at the same rate as the older one (eg, cefoxitin). If the newer agent is more frequently prescribed, for example as physicians attempt to acquire familiarity with the drug, cost savings will be reduced or even eliminated.

Some of the reduction achieved in cefoxitin use has been offset by increased use of other agents, especially cefazolin, in surgical prophylaxis. Since cefazolin is a much cheaper agent than cefoxitin ($2.45/g for cefazolin versus $8.75/g for cefoxitin at our hospital), major overall cost savings will still be achieved and are at least comparable to those that could have been achieved through interchange. It remains to be seen whether cost reductions in cefoxitin use can be maintained over the long term. However, by continuously monitoring cefoxitin use and by forestalling pharmaceutical industry marketing responses to decreased sales by the threat of deleting it from the formulary, we hope to be able to respond if increased use occurs. There might be additional minor cost savings to be achieved by interchanging cefotetan or ceftizoxime for cefoxitin. If the suggested interchange of 1 g cefotetan or ceftizoxime for 2 g cefoxitin is adopted (10,11), and the level of use of October to December 1991 persisted, the annual savings for substituting ceftizoxime would be approximately $17,108, and for cefotetan, $6,580.

At the time this study was initiated, the hospital was undergoing a severe budgetary crisis which ultimately resulted in bed closures and staff layoffs (19). The realization that drug cost savings would reduce the need to lay off staff and close beds likely contributed to medical staff's cooperation in the process. Major users of cefoxitin were asked to participate in the process and draw up their own guidelines for cefoxitin use in surgical prophylaxis. Such a self-directed educational strategy (in which learners are actively involved in the process) may be more effective than passive approaches to physician education, a strategy which has not always been successful (20).
REFERENCES